Posted on April 30, 2021 at 7:30 amUpdated on April 30, 2021 7:42 AM
The BioMap laboratory (BioMedicaments Antiparasitics), common to the University of Tours and INRAE, is preparing the start of clinical trials – phase I – of a coronavirus vaccine from a subunit vaccine containing the key proteins of SARS-CoV-2. This different attitude towards RNA messenger solutions is the result of a call for projects launched by the state during the outbreak of the pandemic last year.
BioMap responded to this with three partners, the CNRS laboratory in Tours and one from the Picardy University, as well as the biotech company Vaxinano from Lille. The National Research Agency (ANR) provided them with 150,000 euros, as well as 100,000 euros from the regional council of the Center-Val-de-Loire.